NASDAQ:ALLO Allogene Therapeutics (ALLO) Stock Forecast, Price & News $3.65 -0.07 (-1.88%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$3.63▼$3.8150-Day Range$3.65▼$5.4152-Week Range$3.63▼$12.21Volume1.51 million shsAverage Volume1.60 million shsMarket Capitalization$611.85 millionP/E RatioN/ADividend YieldN/APrice Target$16.35 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Allogene Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.64 Rating ScoreUpside/Downside347.8% Upside$16.35 Price TargetShort InterestBearish30.26% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 2 Articles This WeekInsider TradingSelling Shares$42,900 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.25) to ($2.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.12 out of 5 starsMedical Sector471st out of 965 stocksBiological Products, Except Diagnostic Industry73rd out of 160 stocks 3.3 Analyst's Opinion Consensus RatingAllogene Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 8 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.35, Allogene Therapeutics has a forecasted upside of 347.8% from its current price of $3.65.Amount of Analyst CoverageAllogene Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted30.26% of the float of Allogene Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllogene Therapeutics has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.Change versus previous monthShort interest in Allogene Therapeutics has recently decreased by 2.01%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAllogene Therapeutics does not currently pay a dividend.Dividend GrowthAllogene Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALLO. Previous Next 1.4 News and Social Media Coverage News SentimentAllogene Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Allogene Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for ALLO on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Allogene Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allogene Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,900.00 in company stock.Percentage Held by Insiders27.40% of the stock of Allogene Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.51% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Allogene Therapeutics are expected to grow in the coming year, from ($2.25) to ($2.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allogene Therapeutics is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allogene Therapeutics is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllogene Therapeutics has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Allogene Therapeutics (NASDAQ:ALLO) StockAllogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Read More ALLO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALLO Stock News HeadlinesSeptember 19, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL), Enanta Pharmaceuticals (ENTA) and ADC Therapeutics (ADCT)September 1, 2023 | insidermonkey.com5 Best High Risk High Reward Stocks To Buy NowSeptember 24, 2023 | Altimetry (Ad)Biden's latest bailout--terrible for America?And a consultant for the Dept. of Defense (Joel Litman) says this is all leading to an event in the next 20 months that could help some get vastly wealthier… but also make it harder than ever to hang onto any money you make.This might be the most important development affecting you and your money over the next few years—August 29, 2023 | finance.yahoo.com16 Most Shorted Stocks Right NowAugust 15, 2023 | markets.businessinsider.comWilliam Blair Sticks to Its Buy Rating for Arcellx Inc (ACLX)August 14, 2023 | markets.businessinsider.comWilliam Blair Sticks to Its Hold Rating for Century Therapeutics (IPSC)August 14, 2023 | finance.yahoo.comAllogene Therapeutics Appoints Earl Douglas as General CounselAugust 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Relay Therapeutics (RLAY), Athira Pharma (ATHA) and Adicet Bio (ACET)September 24, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.August 7, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Allogene Therapeutics (ALLO)August 7, 2023 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Allogene Therapeutics (ALLO)August 4, 2023 | markets.businessinsider.comAllogene Therapeutics (ALLO) Gets a Buy from RBC CapitalAugust 4, 2023 | msn.comOppenheimer Reiterates Allogene Therapeutics (ALLO) Outperform RecommendationAugust 3, 2023 | finance.yahoo.comAllogene's (ALLO) Q2 Loss Narrower Than Expected, Sales MissAugust 2, 2023 | finance.yahoo.comAllogene Therapeutics Reports Second Quarter 2023 Financial Results and Business UpdateJuly 28, 2023 | cnbc.comThese are the most heavily shorted stocks right nowJuly 26, 2023 | seekingalpha.comAllogene: I Am Less Sanguine About Allogeneic CAR-T's Prospects Than BeforeJuly 26, 2023 | finance.yahoo.comAllogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023July 12, 2023 | benzinga.comTruist Securities Maintains Buy on Allogene Therapeutics, Lowers Price Target to $18July 6, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Viracta Therapeutics (VIRX)July 3, 2023 | benzinga.comShort Volatility Alert: Allogene TherapeuticsJune 28, 2023 | markets.businessinsider.comPositive Report for Black Diamond Therapeutics (BDTX) from H.C. WainwrightJune 20, 2023 | benzinga.comHC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $23 Price TargetJune 16, 2023 | benzinga.comAllogene Therapeutics' Allogeneic CAR-T Therapy Proves Potential for LBCL Treatment, Analysts See Potential for First-in-Class StatusJune 16, 2023 | markets.businessinsider.comAnalyst Ratings for Allogene TherapeuticsJune 16, 2023 | fool.comAllogene Therapeutics (NASDAQ: ALLO)June 15, 2023 | finance.yahoo.comAllogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) LuganoSee More Headlines Receive ALLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLO Company Calendar Last Earnings8/02/2023Today9/24/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALLO CUSIPN/A CIK1737287 Webwww.allogene.com Phone(650) 457-2700FaxN/AEmployees359Year Founded2018Price Target and Rating Average Stock Price Forecast$16.35 High Stock Price Forecast$31.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+347.8%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($2.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-332,630,000.00 Net Margins-184,733.34% Pretax Margin-184,733.33% Return on Equity-54.13% Return on Assets-44.03% Debt Debt-to-Equity RatioN/A Current Ratio9.18 Quick Ratio9.18 Sales & Book Value Annual Sales$240,000.00 Price / Sales2,549.37 Cash FlowN/A Price / Cash FlowN/A Book Value$4.62 per share Price / Book0.79Miscellaneous Outstanding Shares167,630,000Free Float121,696,000Market Cap$611.85 million OptionableNot Optionable Beta0.77 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Arie S. Belldegrun F.A.C.S. (Age 74)FACS, M.D., Co-Founder & Exec. Chairman Comp: $714.25kDr. David D. Chang M.D. (Age 63)Ph.D., Co-Founder, Pres, CEO & Director Comp: $1.1MMr. Joshua A. Kazam (Age 46)Co-Founder & Director Comp: $711kYinlin ChenSr. VP of Fin.Mr. Timothy L. Moore Ph.D. (Age 62)Exec. VP & Chief Technical Officer Ms. Barbra SasuChief Scientific OfficerMr. Stephen ChengChief Information OfficerMr. Earl M. Douglas Esq. (Age 60)Gen. Counsel & Compliance Officer Ms. Susan R. Lundeen (Age 57)Chief People Officer Ms. Christine CassianoExec. VP, Chief Corp. Affairs & Brand Strategy OfficerMore ExecutivesKey CompetitorsEditas MedicineNASDAQ:EDIT4D Molecular TherapeuticsNASDAQ:FDMTCabaletta BioNASDAQ:CABAExscientiaNASDAQ:EXAIAmbrx BiopharmaNYSE:AMAMView All CompetitorsInsiders & InstitutionsBarclays PLCBought 168,546 shares on 9/21/2023Ownership: 0.399%Virginia Retirement Systems ET ALBought 125,200 shares on 8/22/2023Ownership: 0.075%Nuveen Asset Management LLCBought 63,186 shares on 8/16/2023Ownership: 0.201%Royal Bank of CanadaBought 4,104 shares on 8/15/2023Ownership: 0.029%Citadel Advisors LLCBought 8,100 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ALLO Stock - Frequently Asked Questions Should I buy or sell Allogene Therapeutics stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALLO shares. View ALLO analyst ratings or view top-rated stocks. What is Allogene Therapeutics' stock price forecast for 2023? 11 analysts have issued twelve-month price targets for Allogene Therapeutics' shares. Their ALLO share price forecasts range from $6.00 to $31.00. On average, they anticipate the company's share price to reach $16.35 in the next twelve months. This suggests a possible upside of 347.8% from the stock's current price. View analysts price targets for ALLO or view top-rated stocks among Wall Street analysts. How have ALLO shares performed in 2023? Allogene Therapeutics' stock was trading at $6.29 at the start of the year. Since then, ALLO shares have decreased by 42.0% and is now trading at $3.65. View the best growth stocks for 2023 here. When is Allogene Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our ALLO earnings forecast. How were Allogene Therapeutics' earnings last quarter? Allogene Therapeutics, Inc. (NASDAQ:ALLO) issued its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.06. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.01 million. Allogene Therapeutics had a negative net margin of 184,733.34% and a negative trailing twelve-month return on equity of 54.13%. The business's revenue was down 48.8% on a year-over-year basis. During the same period last year, the company posted ($0.52) EPS. What ETFs hold Allogene Therapeutics' stock? ETFs with the largest weight of Allogene Therapeutics (NASDAQ:ALLO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Direxion Moonshot Innovators ETF (MOON), Simplify Propel Opportunities ETF (SURI), Range Cancer Therapeutics ETF (CNCR), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Genomics & Biotechnology ETF (GNOM), Horizon Kinetics Medical ETF (MEDX) and What is David Chang's approval rating as Allogene Therapeutics' CEO? 2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Allogene Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP). When did Allogene Therapeutics IPO? (ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO. What is Allogene Therapeutics' stock symbol? Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO." Who are Allogene Therapeutics' major shareholders? Allogene Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (5.06%), BlackRock Inc. (5.04%), JPMorgan Chase & Co. (3.66%), Woodline Partners LP (3.17%), Geode Capital Management LLC (1.09%) and Goldman Sachs Group Inc. (0.89%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Owen N Witte, Owen N Witte, Rafael Amado, Stephen Mayo and Veer Bhavnagri. View institutional ownership trends. How do I buy shares of Allogene Therapeutics? Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Allogene Therapeutics' stock price today? One share of ALLO stock can currently be purchased for approximately $3.65. How much money does Allogene Therapeutics make? Allogene Therapeutics (NASDAQ:ALLO) has a market capitalization of $611.85 million and generates $240,000.00 in revenue each year. The company earns $-332,630,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis. How many employees does Allogene Therapeutics have? The company employs 359 workers across the globe. How can I contact Allogene Therapeutics? Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.allogene.com. The company can be reached via phone at (650) 457-2700 or via email at ir@allogene.com. This page (NASDAQ:ALLO) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.